Alnylam Pharmaceuticals, Inc. (ALNY) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Cambridge, MA, United States. The current CEO is Yvonne L. Greenstreet.
ALNY has IPO date of 2004-06-01, 2,230 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $45.01B.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel RNAi (RNA interference) therapeutics for genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases. The company has three marketed products: ONPATTRO for hereditary transthyretin amyloidosis, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1. Alnylam maintains a robust pipeline of investigational therapies addressing hemophilia, hypertension, hypercholesterolemia, and metabolic liver disease, supported by strategic collaborations with Regeneron Pharmaceuticals and Sanofi Genzyme. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company has established multiple license and collaboration agreements with leading pharmaceutical organizations to advance RNAi-based drug development.
